Gene Editing Therapies Advance on Multiple Fronts
Researchers are reporting a series of breakthroughs in gene editing. In a mouse study, adenine base editing successfully repaired a mutation for a rare neurodevelopmental disorder, restoring protein function and improving learning. Meanwhile, Intellia Therapeutics has completed enrollment for a Phase 3 trial of its therapy for hereditary angioedema, and new results show a CRISPR-based treatment has improved vision in people with inherited blindness.
The adenine base editing technique uses a modified CRISPR-Cas9 system. Instead of cutting the DNA, it uses an enzyme called adenine deaminase to chemically change a single incorrect DNA letter, or base, to the correct one, offering a high degree of precision. This method was recently used in living mice to correct a mutation for a neurodevelopmental disorder called Snijders Blok-Campeau syndrome, restoring normal protein levels and improving social, learning, and motor behaviors. Intellia's therapy for hereditary angioedema, NTLA-2002, also uses CRISPR but works differently. It's an *in vivo* treatment, meaning the editing happens directly inside the body. A single intravenous dose delivers the CRISPR machinery to the liver to knock out the KLKB1 gene. This permanently reduces the production of plasma kallikrein, a protein that triggers the severe swelling attacks characteristic of the disease. The vision-improvement therapy targets a form of Leber congenital amaurosis (LCA), a severe inherited retinal disease. The BRILLIANCE clinical trial involved injecting the CRISPR therapy directly into the eyes of 14 patients to correct a mutation in the CEP290 gene. This approach was taken because the CEP290 gene is too large for traditional gene replacement therapy using adeno-associated viruses (AAV). These breakthroughs are driven by professionals in diverse roles. In the lab, a PhD scientist might lead the research to develop a new base editing technique, while an MD/PhD physician-scientist could design and run the clinical trials, bridging the gap between bench research and patient care. These dual-degree paths are long, often taking 7-9 years before residency, but prepare graduates for careers leading research in academic medical centers. On the tech side, a computational biologist uses mathematical modeling and simulations to understand complex biological systems, like how a genetic mutation leads to disease. A bioinformatics engineer then builds the data pipelines and infrastructure needed to analyze the massive datasets generated from genomic sequencing and clinical trials, ensuring data quality and optimizing workflows. Both roles often require strong programming and statistical skills. Patient-facing roles are crucial for translating these technologies into clinical reality. A genetic counselor, who typically has a master's degree, works directly with patients and families to explain genetic risks, coordinate and interpret tests, and provide support. They might spend their day reviewing family histories, educating patients about a new CRISPR trial, and helping them make informed healthcare decisions. Bringing a new therapy to market involves roles like biotech product development. Professionals in this area manage the process from the lab to manufacturing, ensuring treatments can be produced at a commercial scale. This can involve everything from formulation development and quality assurance to coordinating with manufacturing teams and navigating regulatory affairs.
